<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

CAR-T Cell Therapy: Use Earlier for Better Results

immunotherapy, immuno-oncology model, optimizing car-t cell therapy clinical use, disease burden, first line treatment

immunotherapy, immuno-oncology model, optimizing car-t cell therapy clinical use, disease burden, first line treatmentCAR-T cell therapies are still in their infancy as clinical oncology treatments, with the first agent approved just 6 months ago. It’s known that CD19 specific CAR-T therapies induce high rates of initial response in patients, but as the treatment modality is so new, long term response studies are lacking.

New research published this month in The New England Journal of Medicine has followed patients from a Phase 1 CAR-T cell therapy clinical trial for up to five and a half years, to look at long term benefits of the treatment. Some interesting results have been generated, on which patients respond best to treatment, and when the therapy could be best incorporated into clinical regimens.

CD19 CAR-T Cell Therapy Trialed in Relapsed B Cell Acute Lymphoblastic Leukemia

The initial study looked at testing CD19-specific CAR-T therapies in patients with relapsed B cell ALL, who had received several rounds of chemotherapy before relapse. Of the 53 patients treated, 83% presented with complete remission; however, 14 of the patients experienced severe cytokine release syndrome (as discussed in our previous post, CAR-T therapies can induce severe toxicity and adverse events including CRS which need to be very carefully monitored).

At a median follow-up time of 29 months, the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4) for the whole patient cohort.

Patients with Lowest Disease Levels Showed the Best Response

The study went on to look at how disease levels affected response rate, with some very interesting results which have future implications for how and when CAR-T therapies might be implemented.

The patient cohort was divided based on disease burden – those with a “low” burden before treatment (<5% bone marrow blasts) and those with a higher disease burden (≥5% bone marrow blasts or extramedullary disease).

Patients with a low disease burden had a markedly enhanced duration of remission and survival, with:

  • median event-free survival of 10.6 months (95% CI, 5.9 to not reached)
  • median overall survival of 20.1 months (95% CI, 8.7 to not reached).

This compares with median event-free survival of 5.3 months and median overall survival of 12.4 months for patients with high disease burden.

Patients with Low Disease Burden also Had Fewer Side Effects

As well as an improved response, the patients with a lower disease burden also had lesser incidence of cytokine release syndrome and neurotoxic events compared with high disease burden patients.

Optimize CAR-T Cell Therapy Use: Earlier Adoption, Best Results for Patients with Less Disease

These results give an interesting insight into who might benefit most from CAR-T therapy, and when it might be most useful in a treatment schedule.

Looking at how much cancer a person has before giving CAR-T cell treatment, might be a good gauge of how that patient will respond, and which groups of patients will/will not respond well to the treatment (and therefore who might benefit more from any other available options).

Secondly, these data suggest that CAR-T might be better implemented earlier in a treatment schedule, before patient disease burden becomes too high (potentially following first-line chemotherapy) for the best long term benefit. Current approvals for CAR-T therapies are for patients who are in secondary or later relapse, by which time disease burden may be higher than liked for CAR-T treatment.

As more long term studies read out on this new modality, we’ll gain more information on how to optimize use, and provide the largest survival benefits for the greatest number of patients.

Further Reading:

Related Posts